Abstract: Ion channel dysfunction is known to underlie several acute and chronic disorders and, therefore, ion channels have gained increased interest as drug targets. During the past decade, ion channel screening platforms have surfaced that enable high throughput drug screening from a more functional perspective. These two factors taken together have further inspired the development of more refined screening platforms, such as the automated patch clamp platforms described in this article.
INTRODUCTION
Ion channels are transmembrane protein pores, and are present in almost every cell type throughout the human body. They play a vital role in a multitude of critical functions; every heartbeat, every thought, every memory, even reading this text. So much is reliant on proper ion channel activity and function. Ion channel malfunction is known to be involved in disease and disorders such as deafness, long QT syndrome, hypertension, diabetes and epilepsy [1] . It has also been hypothesized that ion channels play a central role in acute and chronic pain, inflammation and in psychiatric disorders such as schizophrenia and depression.
Ion channels have proven to be amenable to small molecule modulation and are, therefore, very interesting drug targets. This is primarily because of the various binding sites and possible interactions that the ion channels offer. Within the pharmaceutical and biotechnology industry today, huge efforts and resources are spent on ion channel drug screening, not only to find new and better drugs, but also to evaluate drug safety aspects involving ion channels, for example in the heart. Ion channels reside in the cellular membrane, with the membrane spanning part embedded in the hydrophobic lipids, and with two hydrophilic parts facing the intracellular *Address correspondence to this author at the Nanion Technologies GmbH, Erzgiessereistr. 4, D-80335 Munich, Germany; Tel: +49-89-218997972; Fax: +49-89-218997960; E-mail: info@nanion.de and extracellular domain, respectively. Ion channel proteins have proven difficult to crystallize and normally require the membrane environment for maintaining the tertiary structure as well as function. Ion channels are characterized based upon the stimuli required for evoking activity, i.e. opening of the pore. Voltage gated ion channels require a characteristic change in the potential across the membrane to conduct current. Voltage gated ion channels are generally very specific in the ionic species that they allow to pass across the membrane via the pore. Therefore, voltage gated ion channels are often named after the ion for which they are selective for. Another class of ion channel requires the binding of a specific compound for activation to occur. These are referred to as ligand gated ion channels, and are typically named after compound required to open the ion channel.
On the other hand, sensations of touch, for example, are mediated by mechano-sensitive ion channels. These respond to a change in membrane tension, causing the channel to open and ions to flow across the membrane. Cellular assays are commonly used when investigating ion channel function and response to the addition of compounds.
ION CHANNEL SCREENING AND THE PATCH CLAMP TECHNIQUE
Ion channel activity can be monitored using direct or indirect methods. Cellular assays that are widely used within the drug screening industry are voltage sensing or calcium sensing fluorescent dyes, or rubidium efflux assays. If a compound generates a response, it is considered a hit and proceeds to the secondary screening step for further characterization. These assays are functional in the sense that the result reflects the average ion channel activity in a relatively large population of cells. However, they only generate a "Yes/No"-type answer and, because of this limited sensitivity, there is a risk for false negatives and, therefore, missing potential blockbuster drugs.
Functional and high quality ion channel data is preferred as early as possible in the drug screening process. Ideally this is achieved with a high temporal resolution and high signal to noise ratio, thus distinguishing the mode of action and efficacy of the ion channel-drug interaction. In this way, compounds could be discovered from the libraries with increased sensitivity and more precise information on the compound's mode of action. This would, in turn, speed up the development process and prolong the profitable time of a patent. Also, safety aspects of drug candidates should ideally be assessed earlier in the screening process to select and develop target molecules with acceptable safety profiles. Conventional patch clamp, the gold standard and leading star for measurements of ion channel activity, celebrated its 25 th anniversary recently [2] . The patch clamp technique allows for real time measurements of the minute ionic currents passing through ion channels in the cellular membrane of a single cell. Patch clamp has an unprecedented temporal and signal-to-noise resolution for real-time recordings of ion channel activity. Patch clamp data reveals many aspects of the drug and ion channel interaction, which is highly valuable and desirable when selecting and developing promising drug candidates.
There is, however, a serious flipside to the patch clamp technique. Typically, practical patch clamping takes years to learn. Even then, the highly trained patch clamp electrophysiologist has an ultra low throughput in the number of screened cells or compounds per day.
The essentials of patch clamping are the use of a glass micro-electrode coupled to high-grade operational amplifier circuitry. The glass microelectrode has a tip diameter typically of ~1 m and is micromanipulated under visual supervision to gently touch the surface of the selected cell. A brief suction pulse is applied to the glass microelectrode and this ideally initiates the formation of a tight high-ohmic interaction between the cellular membrane and the glass surface. This is referred to as the "giga-seal" since the resistance should be one GOhm or higher, thus enabling high-quality recordings, for example when monitoring small ionic currents mediated by single ion channel events. After the gigaohm seal has been achieved, further brief suction pulses are applied to rupture the patch of membrane covering the tip of the pipette, resulting in the whole-cell configuration. In the whole-cell configuration the glass micro electrode has full electrical access to the cell membrane, allowing for clamping of the membrane potential and recording the ionic currents from the entire ion channel population present in the cell membrane. Voltage protocols and administration of drugs are tools used to characterize and dissect the ion channels expressed in a cell.
The resistance of the pipette in the whole cell configuration is referred to as the access resistance. This is normally higher than the pipette resistance itself because of the membrane fragments which become attached to the inside walls of the micro electrode tip.
A high access resistance will result in erroneous effects on temporal resolution, as well as voltage control over the clamp of the membrane. A poor and slow voltage control of the membrane can result in the ion channel response being faster than that of the change in membrane potential and, therefore, the intended membrane voltage is never reached because of the voltage drop over the pipette. In the case of fast activating and inactivating ion channels such as Nav1.5, the ion channel population would start to inactivate before even reaching the maximum membrane potential. In this particular case, a fluctuating access resistance would surely bring uncertainties in the data, and could wrongly be interpreted as false positives or negatives. It is therefore of high importance to keep the access resistance low and constant throughout the recordings, as well as correcting for it as well as possible.
Conventional patch clamping requires high-grade and expensive equipment such as an anti-vibration table, a microscope and high-end micromanipulators. In addition, a Faraday cage shielding the entire set up is needed. A pipettepuller and a micro-forge are also required for producing the pipettes. The total patch clamp set-up requires a substantial financial investment and also lab space in a building with stable floors, since minute vibrations can rupture the gigaseal. In addition, most parts of the set up require regular maintenance, which can be quite finicky and time consuming.
Despite this, many researchers across the world still use this technique because of the high quality and informative data that can be obtained, revealing detailed information about ion channels and their effectors. However, from a drug screening perspective, the ultra-low throughput associated with conventional patch clamping limits the use of the technique to tertiary screening efforts, as it is typically only capable of characterizing of a few compounds per week. Obviously, this excludes conventional patch clamping in other drug screening phases where the demand for higher throughput is much greater.
AUTOMATED PATCH CLAMPING
The incentive for developing automated electrophysiology platforms is primarily to combine the high data quality achieved with electrophysiological methods, with a format that fits the requirement of high throughput screening. This must also be combined with a user-friendly platform making it accessible to users with limited experience in manual patch-clamping. Most automated patch clamp platforms on the market today utilize planar chips as seal forming substrates. The patch clamp substrate contains a micron sized aperture where the cell is first captured, and then, ideally, a giga-ohm seal is formed with the substrate [3] .
In contrast to the manual patch clamp technique where the cell is approached with a microelectrode, in automated patch clamping, the cell is moved towards the patch clamp substrate, as shown in Fig. (1) . A cell is blindly caught when a droplet of a cell suspension is applied to the chip during the application of suction. Once a cell is caught, suction pulses are automatically applied to obtain a gigaseal and then to achieve the whole-cell configuration. Once the whole-cell configuration has been reached, voltage protocols and drug additions are executed according to pre-programmed protocols. Other than using cell suspensions and the blind method of capturing the cells, the process to obtain the whole-cell configuration is analogous to that of conventional patch clamp. In addition, the process is automated, and can be performed unattended. For a detailed discussion on the historical perspective of the development of the planar patch clamp technique please see [4] .
A major benefit of automated patch clamping is the ability to make measurements in parallel, allowing multiple recordings to be made simultaneously. In addition, the data throughput increases 10-to 100-fold depending on the ion channel under investigation and platform used. In most cases the parallel chip technology is scaleable, thus holding a promise of even higher throughput in future platforms.
Yet another benefit of the planar approach is that the patch clamp technique becomes accessible to more users, regardless of previous experience in electrophysiology. More electrophysiological experiments can be done by these users. This allows for more demanding ion channel projects in terms of the number of ion channel targets and compound screening capabilities. General drawbacks of parallel patch clamping are the requirement of high quality cell suspensions, homogeneously expressed ion channels within the cell population, and the limited accessibility for primary cell preparations.
There are a handful of automated patch clamp platforms on the market today. The first one was the Ionworks HT platform (MDS, formerly MDC; for reference see [5] ), the only platform which meets the high throughput demands of secondary drug screening (10 000s of compounds per day). Later, the Ionworks Quattro was launched, introducing the population patch clamp, where the recording substrate contained multiple apertures for capturing and recording from a multitude of cells [6] . In this way, the recorded currents become larger and average cell to cell differences within a population. Ionworks does not support giga-seal recordings, the seal resistance is on the order of 100 MOhms. Secondly, a pore forming agent, and not suction, is used to permeabilize the cell membrane to gain electrical access to the cell membrane.
The low seal resistance confers low data quality which is not in comparison to conventional patch clamping. In addition, the use of pore formers such as amphotericin, results in a higher access resistance compared to conventional patch clamping, and can, in certain instances, alter the pharmacology of the ion channel under investigation. Another draw- back with the system is the compound administration. The recording electrodes have to be removed in order to make compound addition, so the initial response of the compound cannot be measured. These features limit the Ionworks to measuring cell lines expressing moderate to high levels of ion channels, and excludes direct measurements of ligand gated ion channels, where the current response is instantaneous upon drug addition. Also, many ligand gated ion channels generally exhibit a phenomenon called desensitization, where the current response diminishes despite the constant presence of the drug. This makes the Ionworks sub-optimal for investigations of ligand gated ion channels.
The second platform on the market was the PatchXpress (MDS formerly MDC, formerly Axon Inc.; for reference see [7] ). The PatchXpress supports gigaseal recordings and is capable of performing 16 parallel measurements. It has one perfusion capillary for the addition of compounds to the recording sites.
Another platform, launched in 2004, also allowing true giga-seal recordings is the QPatch from Sophion Biosciences [8] . The patch plates have integrated electronics and solution channels allowing rapid drug administration. Solutions spill out into a waste reservoir that has a limited volume and thereby, limits the number of solution additions to a cell. Recently the QPatch48 was launched, allowing 48 simultaneous recordings. Both the PatchXpress and the Qpatch are dedicated screening platforms. Protocols are pre-programmed and can not be changed on-the-fly during recordings. When the start-button is pressed, the patch chip is commited and can be considered as used, since modifications beyond this point are impossible.
Flyion has a different approach to automated patch clamp, using regular patch pipettes in an inverted manner, adding the cells to the inside of the pipette (Fliptips; for reference see [9] ). The cells are wedged into the micro electrode glass tip and giga-sealed. Flyion also introduced modified patch pipettes where the tip of the patch pipette was expanded (Chiptips), to allow for more controlled administration of solutions. However, since the cell is wedged in the taper of the pipette, substantial amounts of the cell membrane will never be exposed to the surrounding solution, only the glass wall of the pipette, resulting in reduced and variable current responses. Secondly, because of the small dimensions of the pipette, liquid administration is ultimately diffusion limited, which is a limitation when investigating ligand gated ion channels.
THE PORT-A-PATCH AND THE PATCHLINER
Nanion introduced the NPC-1 Port-a-Patch in 2003 (Fig.  1 ). This is a miniaturized patch clamp set-up with a minimal bench top format. In 2006, the NPC-16 Patchliner ( Fig. 2) was launched, which is a fully automated patch clamp workstation supporting true giga-seal recordings from up to eight cells simultaneously. Both platforms use borosilicate glass chips as recording substrates, where patch clamp measurements are possible in the whole-cell, cell-attached and perforated-patch recording configurations. External and internal solution exchange is straightforward with the Port-a-Patch and the Patchliner, allowing modulation of the ion channels internally as well as externally [10] .
Fig. (2).
The fully automated patch clamp workstation for parallel patch clamp recordings, the Patchliner. Cells, solutions and compounds are stored in vials/microtitre plates and are handled and analyzed according to a predefined protocol. On the right, the chip consumable containing 16 patch clamp recording sites is shown, as well as a schematic of a single recording site displaying the cross-channel geometry of the external and internal microfluidic perfusion channels.
The NPC-technology has been thoroughly validated with a wide variety of ion channels and different cell lines, as well as some primary cells. As for the cell lines tested so far, both platforms show fairly consistent success rates for obtaining stable whole-cells (60-80%), independently of cell line used. The NPC-chips routinely give low and stable access resistances, which is important when investigating rapidly activating and/or inactivating ion channels. The access resistance can be compensated and monitored throughout the course of the experiment, eliminating deleterious effects caused by a fluctuating access resistance and, thus, ensuring reliable high-quality data. The NPC-chips are produced with various chip-resistances ranging from 0.5 MOhm to 10 MOhm, and can also be customized to fit specific applications. Low resistance chips are normally used for large cell types, or when a low access resistance is essential for the recordings. High-resistance chips are useful for singlechannel recordings for small, very flexible or fragile cells. For example, when recording from erythrocytes that lack a membrane stabilizing cytoskeleton, high resistance chips are used, minimizing the risk of pulling the cell through the aperture.
In addition, the NPC-chips do not require special treatment or storage conditions. They are stored in vacuumized packages and can be stored at room temperature for 18 months without change in performance. Additionally, if there are unused chambers remaining in the NPC-16 chip cartridge, these can readily be used the following day with unaltered performance.
The Port-a-Patch and the Patchliner are currently used in drug screening and academic research. Both are suitable for ligand gated and voltage gated ion channel screening and research. The Patchliner offers a substantial throughput increase of up to 750 data points per day. At the same time the Patchliner is a flexible research station, allowing on-the-fly modifications of protocols and extensive experimental possibilities described in the following sections.
THE PORT-A-PATCH
The Port-a-Patch is Nanion's entry level device and records from one cell at a time (Fig. 1) . The user adds solutions and cells manually. First, a droplet of internal solution is added to the inside of the chip. The chip is manually mounted on the chip holder so that the recording electrode makes contact with the hanging droplet of internal solution. A small droplet of internal solution is added to the external part of the chip, i.e. the recording chamber. Finally, a droplet of cell suspension is pipetted to the recording chamber. The processes of seal formation and whole cell access are completely automated, but can be interrupted by the user at any time. When the "Start"-button is pressed, the in-house developed software, PatchControl, reads out parameters such as seal resistance, cell capacitance and access resistance from the patch clamp acquisition software, to feedback the appropriate actions to a computerized pump applying suction pulses. A cell is captured from a suspension by suction, and in this way is positioned on top of the aperture. The cell is then sealed and suction pulses are used to break through to the whole cell configuration. Once the whole cell configuration has been reached, the user applies voltage protocols in a similar manner to conventional patch clamp.
Various voltage gated ion channels have been investigated using the Port-a-Patch, for example Nav's, Kv's, hERG, hEAG, CFTR etc. Compounds can be administered either manually, using a pipette, or by using a dedicated perfusion system with a laminar flow chamber. The laminar flow chamber allows for rapid solution exchange with switch times from one solution to the other in the 100 ms range. Therefore, the Port-a-Patch has proven useful for investigating ligand gated ion channels as well as voltage gated ion channels. For example, ligand gated ion channels such as GlyRa1, GABA A , GABA C , 5-HT 3 and TRPV1, have been investigated.
In addition to the external perfusion system, the Port-aPatch has two available add-ons; a device for automated internal solution exchange and a temperature control. With the internal perfusion system, internal solutions can be exchanged in whole-cell recording configuration. In this way, second messengers or drugs can be added directly to the cytosolic face of the membrane for internal ion channel modulation. The internal perfusion system allows for the administration of up to four different solutions to the internal side of the membrane using a micro-capillary for continuous internal solution exchange. Data acquisition is possible throughout the solution switching process.
The third add-on, the temperature control, can be used alone or in conjunction with the external perfusion system for experiments at physiological temperature. There are several reasons to perform experiments at physiological temperature. For example, with ion channels such as hERG and hEAG, current amplitudes increase with elevated temperatures. This is due to the fact that the activation of current responses increases with higher temperature, whereas the inactivation of the currents is unaffected by temperature. This results in increased current amplitudes. Therefore, some researchers argue that experiments and safety testing on hERG are more relevant when performed at physiological temperature compared to room temperature. It has also been reported that the pharmacology of certain compounds can be affected by temperature [11] . This is especially important to consider in safety profiling and testing of potential drug candidates. The temperature control could also be useful for studying ion channels such as TRP-channels that display temperature dependent activation.
THE PATCHLINER
The Patchliner is a fully automated patch clamp workstation capable of recording from eight cells simultaneously (Fig. 2) . It is very flexible in both mode of operation and experimental possibilities. Giga-seals and stable whole-cell recordings are routinely achieved with a high success rate of 60-80%. Recording configurations such as cell-attached and perforated patch are also supported. Three NPC-16 chips can be mounted on the chip loading wagon of the Patchliner. This means that up to 48 experiments can be preprogrammed and executed in stand-alone mode. The Patchliner fills the chip with saline solutions, adds cells and seals the cell automatically. When the whole-cell configuration has been reached, voltage protocols and compound additions are performed according to the pre-programmed protocol. When the sequence of commands has been executed, the Patchliner moves on to the next set of recording chambers and starts with new cells and compounds. The Patchliner is capable of operating unattended, but also allows for on-thefly modifications of the protocol. In this way, the user has full control over the course of the experiments and can intervene at any time. For instance, after completing an experiment and if the cells are still stable, the user can add a new set of drugs or perform a different voltage protocol to the same cells, with just a few clicks of the mouse. This maximizes the output of the NPC-16 chips and gives the user a high level of experimental flexibility and freedom.
The software used to pre-program the actions of the Patchliner is the PatchControl-HT package, which is displayed in Fig. (3) . The platform is HEKA based, in the sense that it uses the PatchMaster software for data acquisition and online analysis. In the PatchControl-HT editor window, all experimental parameters are entered, including everything from addition of solutions to the chip to the actual electrophysiological recordings. Modifications of the protocols are simply achieved by adding functions from a drag-and-drop menu. In addition, these modifications can also be made during an ongoing experiment, giving the user maximum experimental freedom. During the experiments, cell parameters are shown, displaying seal resistance, access resistance and cell capacitance. The oscilloscope window displays the traces, and the online analysis window shows the data of interest, e.g., the maximum current plotted against time. Fig.  (3) shows a screenshot of the PatchControl-HT software, displaying experiments with hERG-blockers which were investigated for the determination of the IC50 values.
Each recording chamber in the NPC-16 chip contains two micro channels, one for administration of solutions to the external side, and the other for the administration of internal solutions. The glass chip containing the aperture is sandwiched between the two micro-channel containing structures, allowing rapid and reliable delivery of solutions to both sides of the cellular membrane of the cell, as seen from the lower picture on the right hand side in Fig. (2) . The use of microchannels minimizes the amount of liquids needed for a complete experiment to as low as 25 L per compound and concentration. Also, it guarantees the rapid and complete exchange of solutions. The solution exchange time for switching of solutions in the extracellular compartment is in the order of 50 ms, which makes the Patchliner suitable for studies of most ligand gated ion channels.
The Patchliner also supports internal solution exchange. In this way, modulators such as second messengers can be added during the course of the experiment, or drugs that are believed to cross the membrane and act internally could be Fig. (3) . Screenshot from the PatchControl-HT software. On the left, all relevant parameters are displayed and an editor window is used to set up an experimental protocol. During operation, the editor shows the current status and the advancement of the protocol. If desired, the protocol can be paused at any time to make changes on-the-fly, which provides great flexibility when running the experiments. On the right, the raw data is displayed in oscilloscope views for each individual recording channel as well as a corresponding online analysis, e.g., current amplitude vs time. Here, eight simultaneous recordings from hERG channels and the time course of drug additions in increasing concentrations for IC 50 determination is displayed.
added to the internal side of the membrane directly. There are no restrictions to the number of additions to the external or the internal microchannels since the waste removal is continuously emptied throughout the experiment.
The compound storage area houses not only most microtiter plates, but also glass test tubes, glass bottles and other containers such as Eppendorf tubes. In this way, compound loss due to adsorption or degradation can be avoided by choosing appropriate compound storage conditions. Cells can also be kept in the storage area and several cell lines can be used during one experimental session. Nanion's automated electrophysiology workstations, the Port-a-Patch and the Patchliner, have been successfully introduced as high quality automated patch clamp platforms for industry and academic users. Both platforms provide high quality patch clamp recordings, capable of true gigaseals and long-term stable recordings, accessible to users without the need for years of practical training. They also offer sophisticated experimental possibilities such as accurate and fast ligand application, temperature control, and internal solution exchange.
In the following sections we will present applications and data from the two platforms, which show their usefulness in ion channel drug screening and academic research.
EXPERIMENTAL SECTION

Nav1.5
Since its introduction in 2003, the Port-a-Patch has been used for investigations of various ligand and voltage gated ion channels. Because of the fast voltage clamp conferred by the glass chip technology caused by the aperture geometry, rapidly activating and inactivating ion channels can be studied accurately, due to a low and stable access resistance. An example is shown in Fig. (4) , showing the hNav1.5 currents recorded from a patch-clamped HEK293 cell in whole cell configuration with the Port-a-Patch. Also, an example of pharmacological modulation is displayed in Fig. (4) , where Nav1.5-currents recorded in the whole-cell configuration were reversibly blocked by Tetrodotoxin (TTX). The pharmacological experiments were conducted using the Patchliner, and the image shows the repeated dose dependent block by TTX with an intermittent wash step. Since manufacturing of NPC-16 chips is based on the same procedure as for the NPC-1 chips used with the Port-a-Patch, the same accurate voltage clamp conditions and low access resistance are obtained thus ensuring reliable data. The accuracy of investigations of sodium channels are highly dependent on a low and controlled access resistance, since a drifting access resistance will alter the amplitude of the response, and could, in the worst case scenario, be interpreted as false negatives or false positives. The Port-a-Patch has also successfully been used for studies of other sodium channels, for example Nav1.2 and Nav1.7, which are the sodium channels displaying the fastest activating and inactivating kinetics.
Glycine Elicited Currents in Ltk Cells
Both the Patchliner and the Port-a-Patch have reliable and fast solution exchange capabilities which make the platforms suitable for most ligand gated ion channels. The Patchliner's microchannels ensure rapid switching of solutions around the cells, typically in the order of 50 ms. An example of a ligand gated ion channel investigated with the Patchliner is shown in Fig. (5) , displaying measurements of glycine activated hGlyR 1 receptors stably expressed in a mouse fibroblast cell line (Ltk). Increasing concentrations of glycine were administered to a patch clamped Ltk-cell in the whole cell configuration. Between each agonist addition, buffer was administered to the cell allowing recovery from receptor desensitization. The EC 50 was determined as 84 ± 14 M, which is in accordance with values obtained with conventional patch clamp. The pharmacological enhancement of the glycine response was also studied with the Patchliner. In these experiments, a low concentration of glycine was co-administered with the positive modulator, to investigate the EC 50 of the modulator and the degree of facilitation compared to a control response obtained by applying the low concentration of glycine in the absence of the positive modulator. In these experiments, up to 30 additions Fig. (5) . (A) Ligand-dependent activation of hGlyR using the Patchliner. Overlay of raw data from one hGlyR 1-expressing L(tk)-cell (holding potential -80 mV). The cell was exposed to increasing concentrations of glycine, where each agonist exposure was followed by a 30 s wash step. Below the patch clamp trace is the Hill plot of normalized and averaged peak currents (n=7), for the determination of EC 50 -value for glycine activation of hGlyR 1-channels (84.7 ± 14 M). Error bars are the standard error around the mean for each concentration. Cells were kindly provided by Astrazeneca, Södertälje. (B) Bicuculline block of GABA receptors stably expressed in HEK293 cells. In these investigations the Patchliner was used, recording from four cells simultaneously. Whole cell currents (holding potential -70 mV) were evoked by administration of GABA, 10 M. The GABA currents were blocked by co-administration of increasing concentrations of bicuculline. Every compound challenge was followed by a wash step. The IC 50 was determined as 1.15 ± 0.24 M which correlates well to the literature.
were made to each cell to obtain a 6-point dose response curve. Since the waste reservoir can be emptied continuously, the Patchliner hardware and software impose no restrictions on the number of additions that can be made to each recording chamber.
In addition, the blocking effect of bicuculline on GABA A receptors expressed in HEK 293 cells was investigated using the Patchliner, as shown in Fig. (5B) . GABA, 10 M, was co-administered with increasing concentrations of bicuculline for the determination of the IC50-value. In between every addition, compound-free buffer was added for recovery for desensitization.
The Port-a-Patch and the Patchliner have been used for investigations of various ligand gated ion channels such as GABA A , GABA C , 5-HT 3 , and as seen in the example below, TRPV1. Both platforms can readily be used for the investigation of the pharmacology of agonists, antagonists and positive modulators, acting on ligand gated ion channels.
TRP Channels
TRP-channels have gained more and more interest in research and drug discovery in recent years, and it is predicted that they will receive even more attention in the time to come. The Port-a-Patch and Patchliner platforms have been used to investigate a number of TRP-channels including TRPV1, TRPM2 and TRPM8. In Fig. (6) , whole cell currents are shown which are mediated by TRPV1-channels. These were elicited by application of 500 nM capsaicin followed by the co-administration of capsaicin with increasing concentrations of the antagonist capsazepine. Four cells were recorded simultaneously. Every compound exposure was followed by a 30 s wash step. Washout of the capsaicin induced response was obtained with one buffer application, as shown in the control trace.
Another feature that makes the Port-a-Patch and Patchliner very relevant for TRP-channel studies are the possibility for temperature control, since TRPV1, and other channels, are activated by heat. The temperature control unit for the Port-a-Patch is described below.
ADVANCED APPLICATIONS Experiments at Physiological Temperature
The Port-a-Patch has interesting features allowing sophisticated experiments for ion channel research. One of them has already been mentioned: temperature control. Ion channels, such as some of the TRPs, are activated in specific temperature ranges. The hERG channel, on the other hand, shows altered kinetics with increased temperature and it has been reported that compounds display altered pharmacology at physiological temperatures, as compared to room temperature. During the past few years, the hERG channel has received more and more attention because of its known promiscuity in its interactions with a wide variety of drugs. Interactions with hERG can lead to a prolonged QT interval (i.e. repolarization of the ventricles in the heart), which in turn can result in cardiac arrest and death. This has led to the withdrawal of several blockbuster drugs such as Terfenadine and Cisapride, which is extremely costly for drug developers. However, it is important to point out that a hERG active substance can still be a good drug candidate. In vitro studies do not always correlate with in vivo studies and if the active concentration range of the drug is far below the concentrations where it is affecting the hERG channel, it might still be a good drug candidate.
Since the kinetics of hERG are different at room temperature compared to physiological conditions, it is preferable to perform hERG studies at elevated temperatures. At physiological temperature, hERG current amplitudes increase due to a temperature dependent decrease in the inactivation kinetics. Activation kinetics are unaltered and thus, ion channels spend a longer time in the conducting state resulting in increased current amplitudes.
The effect of temperature on pharmacology has been investigated previously, and some of the experiments were Fig. (6) . TRPPV1 currents were evoked by the application of 500 nM Capsaicin to a cell, patch-clamped in the whole cell configuration (holding potential -80mV). Subsequently, the capsaicin currents were blocked by the co-administration of capsaicin (500 nM) and increasing concentrations of the antagonist capsazepine (60, 200, 600, 2000 and 6000 nM). Every compound exposure was followed by a prolonged wash step. The IC 50 value for capsazepine was determined as 100 ± 20 nM.
repeated using a HEK-cell line expressing the hERG channels (Fig. 7) . Experiments were performed at physiological temperature (35 ± 2°C), and the current amplitude increased almost 2-fold due to the altered inactivation kinetics of hERG at elevated temperatures. The dose dependent block of quinidine was investigated at physiological temperature as well as at room temperature.
Automated Internal Perfusion
Internal solutions can be readily exchanged in experiments with the Patchliner and the Port-a-Patch. In Patchliner experiments the internal solutions are administered by the robotic pipettor through dedicated micro fluidic channels. Exchange is fast, in the order of 10 seconds, and in most cases, obtained with a maintained giga-seal, with no limita Fig. (7) . Temperature controlled experiments were performed using the Port-a-Patch. The trace on the left shows hERG-mediated currents at room temperature (black trace) and physiological temperature (grey trace). There was a dramatic increase in peak amplitude, increasing by 64 ± 9% (n = 13) at 35 ± 2°C). The time to peak decreased by 70 ± 2% (n = 13). The decay phase could be fit using an exponential equation the time course for decay was decreased by 52 ± 4% (n = 12). The panel on the right a full dose response curve for quinidine achieved at 35 ± 2°C. Quinidine blocked the hERG-mediated current in a dose dependent manner, the IC 50 was estimated to be 1.3 ± 0.2 M at 35 ± 2°C (n = 5). This value corresponded well with the estimated IC 50 recorded at room temperature (1.0 ± 0.03 M; n = 3) and is in good agreement with values reported in the literature. tions to the number of additions that can be made, since the Patchliner automatically removes waste.
In the data examples displayed in Fig. (8) , the Port-aPatch was used with the system for automated internal solution exchange. In the top panel, Kv1.3-currents endogenously expressed in Jurkat cells, were repeatedly blocked by the administration of cesium ions internally. Every Cs-block was followed by application of control K + -containing internal solution, which shows complete washout of the Cs-ions and total recovery of the Kv1.3-current. The Kv1.3-current amplitude was stable over a prolonged period of time (35 minutes) where the internal solution replacement was repeated 19 times. In the lower panel, hERG currents were blocked, also using the Port-a-Patch and the internal perfusion system, by the internal administration of tetra-ethyl ammonium (TEA). Every TEA application was followed by a wash step, applying control internal solution.
Recordings from Primary Cells, Stem Cells and Organelles
Both platforms described in this article have been used with primary cells and primary cell cultures, such as erythrocytes, T-lymphocytes, human lung epithelial cells. In addition, mouse primary neuronal stem cells extracted from E14 fetuses and human stem cell derived cardiomyocytes have been investigated using the Port-a-Patch. In Fig. (9) , wholecell currents obtained from a stem cell from mouse brain, show outwardly rectifying behavior.
In addition, single channel recordings from a mitochondrion were acquired with the Port-a-Patch, as shown in Fig.  (9) . Mitochondria were isolated from rat cardiac tissue and the single channel recordings were made in the cell-attached recording configuration. Single channel currents were elicited by a voltage ramp from 0 mV to -80 mV. Due to the cell attached configuration inward currents are displayed as a positive current (Fig. 9) .
Bilayer Recordings
Nanion's patch clamp instrumentation can also be used for patch clamp recordings from artificial lipid bilayers, well known as black lipid membranes or BLMs. Bilayer recordings are attractive for investigations of membrane proteins not accessible to patch clamp analysis, e.g., proteins from organelles. As an example, we present recordings of the outer membrane protein F (OmpF) from Escherichia coli. OmpF is a non-specific transport channel present in the outer membrane of E. coli. The OmpF protein is constituted from three monomers forming a trimer. The porin has been shown to play a major role in the bacterial resistance against antibiotics.
The OmpF protein was reconstituted into giant unilammelar lipid vesicles (GUVs) to form proteoliposomes, which were positioned onto the aperture of the patch clamp chip, much like an artificial cell. Upon touching the glass surface the vesicles burst and form a planar lipid bilayer containing the protein of interest. This automated step greatly facilitates lipid bilayer recordings and allows for the rapid and efficient analysis of ion channel proteins in lipid bilayers under controlled electrophysiological conditions.
With the reconstituted OmpF in proteoliposomes, characteristic trimeric conductance levels were observed with the typical gating induced by application of transmembrane voltage (Fig. 10) . For a more detailed description of this approach and thorough analysis of OMPF in lipid bilayers on the Port-a-Patch, please see [12] [13] .
Brief Agonist-Applications with the Patchliner Using Stacked Solutions
In order to minimize exposure times of ligands, we employed stacking of solutions in the Patchliner's pipettor. In data shown in Fig. (11) , GABA containing solution and extracellular buffer were stacked in the pipette. First, 100 L buffer was drawn into the pipette, followed by 30 L of GABA-solution. In this way, when applying the stack to the recording chamber, the cell was first exposed to the GABAsection of the stack, and then to the following buffer zone.
In Fig. (11) the whole-cell currents from four cells are displayed, elicited by 1, 3 and 10 M of GABA. In the experiments we used a HEK-cell line stably expressing GABAreceptors with a holding potential of -70 mV. The total exposure time to GABA was 1 s. The presented data indicates that exposure times can be as low as 400 ms (Fig. 11) . In this way, exposure times can be shortened to as low as 400 ms. This might prove useful when investigating ligand gated ion channels that rapidly desensitize in a time dependent manner.
CONCLUSION AND OUTLOOK
Most automated patch clamp systems on the market have found their specific market niche fulfilling different market requirements. The Port-a-Patch and Patchliner are being used in labs around the globe in both academia and industry. The instrumentation has proven its usefulness as an ion channel screening platform, as well as an excellent research platform, due to the immense flexibility and experimental freedom it offers. These platforms are both providing high quality data comparable to that of conventional patch clamping, with a substantially higher throughput. In addition, the experimental freedom and versatility allows for sophisticated patch clamp experiments. Outstanding examples are automated internal perfusion, temperature control, experiments with primary cells and rapid administration and wash out of drugs to the external side of the membrane. Taken together with the increased throughput (up to 750 data points per day), these platforms have tremendous potential in making ion channel research and drug development faster and accessible to users not trained in conventional patch clamping.
Ion channel research is thriving in industry and academia alike. With the new available techniques on the market today we have the possibility to learn more about ion channels in a much shorter time, to understand about disease mechanisms that are coupled to ion channel malfunction and possible cures. There are many examples of drugs that target ion channels today and the number of drug candidates targeting ion channel in the cell membrane or organelle membrane is likely to increase. A relevant and interesting example of a drug targeting a specific ion channel can be found in cancer research. Glioblastoma is the most aggressive and lethal of all brain cancers and ion channel research and drug screening in this area has the potential of saving affected persons, who otherwise are facing a rapid and certain death. Specifically, a compound affecting chloride channels in glioblastoma cells, has been developed and undergone phase 2 studies with promising results. By blocking chloride channels present in the glioblastoma cells, it prevents the cancer cells from migrating and further invade the tissue. This in turn limits the progression of the tumor and extends the life time of the patient [14] .
Increased throughput in drug development for ion channel modulators ultimately results in getting better ion channel active drug candidates, so that better compounds can be developed quicker and with known and acceptable safety profiles. This clearly is an important, enabling step for the pharmaceutical industry, as well as academic research, making ion channel screening more affordable and available to a broader user spectrum. Automated patch clamp technology will hence be an important and valuable tool in drug development efforts for years to come.
